Federated Hermes, Inc. Aprea Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 13, 2023	SELL	$0.32 - $15.2 $387 - $18,422	-1,212 Reduced 34.98%	2,253 $0
Q3 2022 Nov 14, 2022	SELL	$0.71 - $13.6 $160 - $3,073	-226 Reduced 6.12%	3,465 $2,000
Q2 2022 Aug 15, 2022	BUY	$0.62 - $1.94 $84 - $265	137 Added 3.85%	3,691 $3,000
Q1 2022 May 13, 2022	BUY	$1.59 - $3.16 $77 - $154	49 Added 1.4%	3,554 $7,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $5.58 $3,880 - $7,544	1,352 Added 62.8%	3,505 $10,000
Q3 2021 Nov 15, 2021	BUY	$3.43 - $5.63 $1,080 - $1,773	315 Added 17.14%	2,153 $11,000
Q2 2021 Aug 16, 2021	BUY	$4.05 - $5.5 $7,095 - $9,636	1,752 Added 2037.21%	1,838 $9,000
Q1 2021 May 13, 2021	BUY	$4.73 - $8.15 $406 - $700	86 New	86 $1,000

Others Institutions Holding APRE

# of Institutions

1

Shares Held

0

Call Options Held

0

Put Options Held

0

Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.